Search
Selected Filter
Displaying 11–20 of 211 research results
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
The emerging therapy is designed to work independent of the mutated gene causing vision loss
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
The company is also expanding its Phase ½ trial for the emerging treatment
-
A Phase 3 trial for the treatment is planned
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
The goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Tiny implant provides continual delivery of anti-VEGF treatment for six months
-
Nacuity’s Emerging Anti-Oxidative Therapy Moves into Clinical Trial
The oral treatment shows promise for slowing vision loss in people with RP and Usher syndrome, regardless of genetic profile
-
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
The gene therapy is designed to reduce the treatment burden for patients
-
jCyte Enters into Licensing Agreement with Santen Pharmaceutical for Cell Therapy
Emerging treatment designed to preserve vision for people with RP and related conditions
